2.4000 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||2.0400 x 2900|
|Ask||2.5000 x 1300|
|Day's Range||2.3800 - 2.4450|
|52 Week Range||2.1500 - 6.3000|
|Beta (3Y Monthly)||2.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.50|
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
PLYMOUTH MEETING, Pa., Aug. 19, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients with precancerous lesions of the anus, i.e. VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied for the treatment of HPV-related precancerous lesions and the HPV infection that causes these lesions.
Inovio (INO) delivered earnings and revenue surprises of -7.14% and -97.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
PLYMOUTH MEETING, Pa. , Aug. 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of synthetic ...
Inovio Pharmaceuticals, a Montgomery County biotechnology company, closed a $15 million private placement of convertible bonds — and disclosed plans to pursue a secondary listing on the KOSDAQ exchange in Korea. If it is successful, Invoio (Nasdaq: INO) said it would become the first U.S.-based Nasdaq company to dually list its stock on the Korean exchange. "The Korean capital market represents an expanding opportunity for Inovio to secure a new and attractive source of capital," said J. Joseph Kim, Inovio's co-founder and CEO.
PLYMOUTH MEETING, Pa., Aug. 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the closing of a private placement in the form of convertible bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15 million based on the current exchange rate) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea, with additional offices in Shanghai, China and Sunnyvale, California. Inovio expects to use the proceeds of the investment for the continued advancement of development activities for its clinical-stage product pipeline and for working capital and other general corporate purposes.
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLYMOUTH MEETING, Pa. , July 30, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that second quarter 2019 financial results will be released after the market close on August ...
PLYMOUTH MEETING, Pa., July 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced that positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS) were published in The Lancet Infectious Diseases. This peer-reviewed article entitled, "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial," highlights clinical results of Inovio's collaborative vaccine study of INO-4700 (also called GLS-5300) against MERS delivered with the CELLECTRA® efficacy-enhancing device. Dr. J. Joseph Kim, Inovio President and CEO, said, "This latest publication underscores the potential for rapid deployment of Inovio's DNA vaccines.
Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.
The Montgomery County biotech company says it wants to focus on the commercial development of its late-stage drug candidates targeting the human papillomavirus.
Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, and Staff by 28% Management to Host Conference Call on July 17 at 8:00 AM EDT PLYMOUTH MEETING, Pa. , July 16, 2019 /PRNewswire/ -- Inovio ...
In 2009 J. Kim was appointed CEO of Inovio Pharmaceuticals, Inc. (NASDAQ:INO). This analysis aims first to contrast...
PLYMOUTH MEETING, Pa., July 10, 2019 /PRNewswire/ -- Geneos Therapeutics, a clinical-stage biotech company, a spin-out of Inovio Pharmaceuticals (INO), announced today that the first cancer patient was dosed using the company's GT-EPIC Neoantigen-Targeting Personalized Vaccine Technology. In this first-in-human treatment – part of a clinical collaboration between Geneos and Washington University School of Medicine in St. Louis – a patient with Anaplastic Astrocytoma, a form of advanced brain cancer, is being treated on a Compassionate Use basis with the patient's own tumor-derived neoantigen vaccine.
PLYMOUTH MEETING, Pennsylvania, July 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied for the treatment of HPV-related precancerous lesions and the HPV infection that causes these lesions. Inovio is already evaluating VGX-3100 in two Phase 3 registration trials (REVEAL 1 and REVEAL 2) to treat cervical dysplasia caused by HPV.
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV). Left untreated, cervical dysplasia can progress to cervical cancer. If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.